FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954960507> ?p ?o ?g. }

• W2954960507 abstract "Protein arginine methyltransferase 5 (PRMT5) is an epigenetic enzyme with oncogenic properties. JNJ-64619178 (JNJ178) is a potent, selective, structurally unique PRMT5 inhibitor with good preclinical efficacy in inhibiting the growth of hematologic and solid tumor cell lines. Toxicology studies showed that JNJ178 decreased reticulocytes and neutrophils in rats and dogs. The objectives of translational modeling and simulation were to understand the exposure-response relationship of both safety and efficacy and provide guidance to the first-in-human clinical development of JNJ178. Experimental data for the PK/PD (Pharmacokinetics/Pharmacodynamics) modeling included: plasma concentration after single dose of JNJ178 in non-tumor bearing mice, plasma concentration and PD markers of dimethylation of arginine (%SDMA in plasma and %SMD1/3-Me 2 in tumor, respectively) after multiple doses (1 to 10 mg/kg) QD (once daily) of JNJ178 in H1048 (human small cell lung carcinoma) xenografts, and tumor volume in four xenograft mouse models (A427, human lung carcinoma; H441, human lung adenocarcinoma; H520, human squamous cell lung carcinoma; and H1048). Plasma PK were first described by a standard two-compartment model and used as a driver of PD and tumor volume (efficacy). Plasma and tumor PD were modeled using an indirect response model. A hybrid tumor growth coupled with transit compartment mediated tumor killing model was used to fit the tumor volume data. To predict the safety profile of JNJ178, lifespan based indirect response model for erythropoiesis and Friberg myelosuppression model were used to simulate hemoglobin and neutrophil kinetics in human. The PK/PD model described the data well and validated the hypothesis that PD is driven by trough concentration. Based on the exposure-response relationship from the four xenograft models, the trough concentration needed to achieve tumor stasis for mouse was determined. In addition, the level of inhibition in tumor and plasma PD marker that was associated with tumor stasis was identified. Together with human PK parameters scaled using allometry, the dose range needed to achieve target therapeutic exposure for a typical human subject was predicted. Simulation results from erythropoiesis and Friberg myelosuppression models informed the optimal doing schedules for certain dose levels that would allow hematological toxicity to be manageable with 1.0 x 10 9 /L neutrophil counts at all times. Overall, a translational modeling and simulation approach that considers safety and efficacy has been instrumental in the design of the first-in-human clinical development of PRMT5 inhibitor JNJ178 regarding selection of dose and schedule. Citation Format: Yue Guo, Nahor Haddish-Berhane, Hillary J. Millar, Tinne Verhulst, Tony Greway, Junguo Zhou, Loeckie DeZwart, Dana Gaffney, Joseph Portale, Dirk Brehmer, An Boeckx, Erika Van Heerde, Daniele Ouellet. Translational efficacy and safety modeling and simulation to support the clinical development of JNJ-64619178, a PRMT5 inhibitor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3905." @default.
• W2954960507 created "2019-07-12" @default.
• W2954960507 creator A5001032583 @default.
• W2954960507 creator A5009013904 @default.
• W2954960507 creator A5021683079 @default.
• W2954960507 creator A5023701680 @default.
• W2954960507 creator A5023758850 @default.
• W2954960507 creator A5036024856 @default.
• W2954960507 creator A5036543488 @default.
• W2954960507 creator A5046157866 @default.
• W2954960507 creator A5047840816 @default.
• W2954960507 creator A5048929341 @default.
• W2954960507 creator A5064747201 @default.
• W2954960507 creator A5083560128 @default.
• W2954960507 creator A5086102379 @default.
• W2954960507 date "2019-07-01" @default.
• W2954960507 modified "2023-09-27" @default.
• W2954960507 title "Abstract 3905: Translational efficacy and safety modeling and simulation to support the clinical development of JNJ-64619178, a PRMT5 inhibitor" @default.
• W2954960507 doi "https://doi.org/10.1158/1538-7445.sabcs18-3905" @default.
• W2954960507 hasPublicationYear "2019" @default.
• W2954960507 type Work @default.
• W2954960507 sameAs 2954960507 @default.
• W2954960507 citedByCount "0" @default.
• W2954960507 crossrefType "proceedings-article" @default.
• W2954960507 hasAuthorship W2954960507A5001032583 @default.
• W2954960507 hasAuthorship W2954960507A5009013904 @default.
• W2954960507 hasAuthorship W2954960507A5021683079 @default.
• W2954960507 hasAuthorship W2954960507A5023701680 @default.
• W2954960507 hasAuthorship W2954960507A5023758850 @default.
• W2954960507 hasAuthorship W2954960507A5036024856 @default.
• W2954960507 hasAuthorship W2954960507A5036543488 @default.
• W2954960507 hasAuthorship W2954960507A5046157866 @default.
• W2954960507 hasAuthorship W2954960507A5047840816 @default.
• W2954960507 hasAuthorship W2954960507A5048929341 @default.
• W2954960507 hasAuthorship W2954960507A5064747201 @default.
• W2954960507 hasAuthorship W2954960507A5083560128 @default.
• W2954960507 hasAuthorship W2954960507A5086102379 @default.
• W2954960507 hasConcept C104317684 @default.
• W2954960507 hasConcept C111113717 @default.
• W2954960507 hasConcept C111819275 @default.
• W2954960507 hasConcept C112705442 @default.
• W2954960507 hasConcept C126322002 @default.
• W2954960507 hasConcept C185592680 @default.
• W2954960507 hasConcept C33288867 @default.
• W2954960507 hasConcept C502942594 @default.
• W2954960507 hasConcept C55493867 @default.
• W2954960507 hasConcept C71924100 @default.
• W2954960507 hasConcept C91965660 @default.
• W2954960507 hasConcept C98274493 @default.
• W2954960507 hasConceptScore W2954960507C104317684 @default.
• W2954960507 hasConceptScore W2954960507C111113717 @default.
• W2954960507 hasConceptScore W2954960507C111819275 @default.
• W2954960507 hasConceptScore W2954960507C112705442 @default.
• W2954960507 hasConceptScore W2954960507C126322002 @default.
• W2954960507 hasConceptScore W2954960507C185592680 @default.
• W2954960507 hasConceptScore W2954960507C33288867 @default.
• W2954960507 hasConceptScore W2954960507C502942594 @default.
• W2954960507 hasConceptScore W2954960507C55493867 @default.
• W2954960507 hasConceptScore W2954960507C71924100 @default.
• W2954960507 hasConceptScore W2954960507C91965660 @default.
• W2954960507 hasConceptScore W2954960507C98274493 @default.
• W2954960507 hasLocation W29549605071 @default.
• W2954960507 hasOpenAccess W2954960507 @default.
• W2954960507 hasPrimaryLocation W29549605071 @default.
• W2954960507 hasRelatedWork W1999354530 @default.
• W2954960507 hasRelatedWork W2000756020 @default.
• W2954960507 hasRelatedWork W2021712271 @default.
• W2954960507 hasRelatedWork W2039667226 @default.
• W2954960507 hasRelatedWork W2320791948 @default.
• W2954960507 hasRelatedWork W2321809039 @default.
• W2954960507 hasRelatedWork W2397118204 @default.
• W2954960507 hasRelatedWork W2416777431 @default.
• W2954960507 hasRelatedWork W2519978239 @default.
• W2954960507 hasRelatedWork W2560286577 @default.
• W2954960507 hasRelatedWork W26958604 @default.
• W2954960507 hasRelatedWork W2741918365 @default.
• W2954960507 hasRelatedWork W2786667163 @default.
• W2954960507 hasRelatedWork W2954592211 @default.
• W2954960507 hasRelatedWork W2955415793 @default.
• W2954960507 hasRelatedWork W2955504684 @default.
• W2954960507 hasRelatedWork W2994342338 @default.
• W2954960507 hasRelatedWork W3082051191 @default.
• W2954960507 hasRelatedWork W3177802895 @default.
• W2954960507 hasRelatedWork W3199839623 @default.
• W2954960507 isParatext "false" @default.
• W2954960507 isRetracted "false" @default.
• W2954960507 magId "2954960507" @default.
• W2954960507 workType "article" @default.